The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Marina Chiara Garassino and James Dolezal.
Connection Strength

0.914
  1. What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? Ther Adv Med Oncol. 2023; 15:17588359231198446.
    View in: PubMed
    Score: 0.232
  2. Deep learning generates synthetic cancer histology for explainability and education. NPJ Precis Oncol. 2023 May 29; 7(1):49.
    View in: PubMed
    Score: 0.228
  3. Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology. Nat Commun. 2022 11 02; 13(1):6572.
    View in: PubMed
    Score: 0.219
  4. Developing a low-cost, open-source, locally manufactured workstation and computational pipeline for automated histopathology evaluation using deep learning. EBioMedicine. 2024 Sep; 107:105276.
    View in: PubMed
    Score: 0.062
  5. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC. J Thorac Oncol. 2024 Jul; 19(7):1108-1116.
    View in: PubMed
    Score: 0.060
  6. PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis. J Immunother Cancer. 2023 06; 11(6).
    View in: PubMed
    Score: 0.057
  7. The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. Clin Lung Cancer. 2023 06; 24(4):381-387.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.